Effects of Ca2+/calmodulin‑dependent protein kinase pathway inhibitor KN93 on osteoclastogenesis

Int J Mol Med. 2018 Oct;42(4):2294-2302. doi: 10.3892/ijmm.2018.3793. Epub 2018 Jul 25.

Abstract

The aim of the present study was to determine the effects of the Ca2+/calmodulin‑dependent protein kinase pathway inhibitor KN93 on osteoclastogenesis. RAW264.7 cells were incubated with macrophage colony‑stimulating factor (M‑CSF) + receptor activator of nuclear factor kappa‑light‑chain‑enhancer of activated B cells ligand (RANKL) to stimulate osteoclastogenesis and then treated with 10 µM KN93. The methods included tartrate‑resistant acid phosphatase (TRAP) staining, bone resorption activity assays, filamentous (F)‑actin staining, determination of intracellular calcium ([Ca2+]i) levels, monitoring of osteoclast‑specific gene expression levels and measurement of key transcription factors protein levels. The results suggested that KN93 inhibited the formation of TRAP‑positive multinucleated cells, shaping of F‑actin rings and resorption activity of the cells. In addition, KN93 decreased the concentration of [Ca2+]i, expression levels of osteoclast specific genes and protein levels of critical transcription factors in the M‑CSF + RANKL‑induced osteoclast model. In summary, KN93 may directly affect the differentiation and activation of osteoclasts, potentially through the Ca2+/calmodulin‑dependent protein kinase signaling pathway.

MeSH terms

  • Animals
  • Calcium / metabolism*
  • Calcium Signaling / drug effects*
  • Calmodulin / metabolism*
  • Mice
  • Osteoclasts / cytology
  • Osteoclasts / metabolism*
  • Protease Inhibitors / pharmacology*
  • RANK Ligand / metabolism
  • RAW 264.7 Cells

Substances

  • Calmodulin
  • Protease Inhibitors
  • RANK Ligand
  • Tnfsf11 protein, mouse
  • Calcium